Pharmaceutical filing citing a Journal of the American College of Cardiology paper — Cytokinetics, 2025-09-03
CytokineticsCytokineticsNASDAQ CYTK
Filings SEC · Quote Yahoo cited a paper published in the Journal of the American College of Cardiology in its regulatory filing with the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website as the basis for its claims. The company read the manner in which it wrote the paper and the scope the paper actually demonstrated in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure is written in the press release as follows:
When a U.S. listed company has something to inform shareholders, it submits a 8-K to the Securities and Exchange Commission. The item numbers of this document submitted by Cytokinetics on 2025-09-03 were 8.01 Other Events · 9.01 Financial Statements and Exhibits. The company cited a paper published in Journal of the American College of Cardiology in the attached press release. If the sentence citing the paper is translated verbatim, it reads as follows:
Effect of Aficamten Compared with Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM. JACC. 2025.
What a reader should first check is where the company placed the paper in the press release. Next, the reader should determine whether the paper supports the company's entire claim or only a part of it. To answer the latter question, one must read the full paper. This article, which has only read the abstract, cannot provide an answer.
The scope of the paper mentioned in the abstract is limited to this.
The paper's title is Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy and it was published in Journal of the American College of Cardiology on 2025-08-27. The authors are affiliated with Southwestern Medical Center · The University of Texas Southwestern Medical Center · Brigham and Women's Hospital · Harvard University. The summary at the beginning of the paper is called abstract. This article has read only up to this point. The paragraph was written by a person after filtering a draft written by a machine by comparing numbers, so it is of a different grade than a full reading of the paper.
This is an echocardiographic analysis comparing apicamten monotherapy with metoprolol, the long-standing standard treatment, in patients with obstructive hypertrophic cardiomyopathy who have symptoms. In a previous trial, apicamten reduced the pressure gradient in the left ventricular outflow tract and improved relaxation function compared to a placebo. This time, the researchers compared how the structure and function of the heart changed over time when each drug was used alone, using repeated ultrasound images. The numerical results are in the latter part of the abstract. This article does not include that part.
What the abstract does not answer remains in the full paper and the appendix. This article, which has not gone beyond the abstract, leaves the blanks as they are. Readers should compare the two citations above to determine which sentence in the abstract corresponds to the citation provided by the company.
One month later, the stock price was within the upper quartile of the sample.
The remaining return, after subtracting the portion that moves with the overall market, is called excess return. The date is written as a trading day, counting only the days the stock market is open. In calendar terms, 20 trading days are approximately one month. The excess return for the day of the regulatory filing and the following month are listed in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| Five trading days before the filing | +35.8% | The extent of movement before the filing |
| On the day of the filing | +0.8% | On the filing day or the first trading day thereafter |
| Accumulated over +1 to +5 trading days | +3.3% | One week |
| Cumulative +1~+20 trading days | +6.7% | One month |
A collection of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of +6.7% in this case is within the top quarter, corresponding to the 77% position from the bottom among 142 cases in the sample.
| Sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | median | top 25% | top 10% | This case |
|---|---|---|---|---|---|---|
| Excess return | −31.9% | −20.1% | −7.4% | +5.5% | +19.5% | +6.7% |
Half of the sample falls between the two central marks in the chart. One checks from the chart whether this case lies inside or outside. The sample collects cases where U.S. listed companies wrote papers in 8-K over the past ten years. The company itself is excluded from the sample. The numbers written here are past facts, not rules to apply to the next case.
There are two additional cases where the same company wrote papers in 8-K, and they are placed together in the table below.
| Disclosure date | the journal of the paper | a month of excess return |
|---|---|---|
| 2024-05-13 | New England Journal of Medicine | −5.4% |
| 2025-09-08 | Journal of the American College of Cardiology | +9.8% |
after the filing, the company issued such documents
after the filing date, the company issued three 8-K filings. Only the item numbers are listed here. In 8-K filings without titles, the item numbers indicate the type of content. Whether it was an earnings announcement or a contract can be determined by the number. The details of what occurred are read in the original text of each link.
- 2025-09-16 8-K Item 8.01 — Other Events
- 2025-09-22 8-K Items 1.01, 2.03, 3.02, 8.01, 9.01 — Material contracts entered into · Debt issuance · Sale of unregistered securities · Other events · Financial statements and exhibits
- 2025-11-05 8-K Items 2.02, 9.01 — Earnings announcement · Financial statements and exhibits
What this article does not answer
This article, which reads only abstracts, does not answer how the paper reviewed what method, what it re-examined, and how far it showed. How often the paper cited by the company has been cited afterward can be rechecked through the OpenAlexOpenAlex
Data source · Website citation count. What will be seen next is whether the company's next 8-K again cites the same paper.
Term explanation
- 8-K
- A periodic report submitted to the Securities and Exchange Commission when a listed company in the United States has something to inform its shareholders. The types are indicated by item numbers such as earnings, contracts, and executive changes. All the events in this article are derived from this document.
- Excess return
- The remainder obtained by subtracting the overall market return from the stock return. It is used to observe the movement of the company alone after removing the portion where the market as a whole rises or falls.
- Trading day
- A date counted only on days when the stock market is open. Since weekends and holidays are excluded, 20 trading days correspond to roughly one calendar month.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- A summary placed at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full text, one cannot know the details and limitations of the method.